{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:35:00Z","timestamp":1791560100559,"version":"4.3.4"},"reference-count":20,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T00:00:00Z","timestamp":1693958400000},"content-version":"am","delay-in-days":432,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.clinthera.2022.06.004","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T07:54:10Z","timestamp":1656489250000},"page":"1028-1032","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Vedolizumab as the First-Line of Biologicals for Pediatric Patients With Ulcerative Colitis"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9995-5522","authenticated-orcid":false,"given":"Toshihiko","family":"Kakiuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Yoshiura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2022.06.004_bib0001","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1124\/jpet.109.153973","article-title":"The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases","volume":"330","author":"Soler","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2022.06.004_bib0002","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn's disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.clinthera.2022.06.004_bib0003","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1093\/ecco-jcc\/jjx082","article-title":"Vedolizumab in paediatric inflammatory bowel disease: a retrospective multi-centre experience from the paediatric IBD Porto Group of ESPGHAN","volume":"11","author":"Ledder","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.clinthera.2022.06.004_bib0004","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1007\/s00431-021-04063-6","article-title":"Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study","volume":"180","author":"Garcia-Romero","year":"2021","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.clinthera.2022.06.004_bib0005","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/MPG.0000000000002035","article-title":"Management of paediatric ulcerative colitis, part 1: ambulatory care\u2014an evidence-based guideline from European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition","volume":"67","author":"Turner","year":"2018","journal-title":"J Pediatr Gastroenterol Nutrition"},{"key":"10.1016\/j.clinthera.2022.06.004_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105120","article-title":"Biological therapy in pediatric age","volume":"161","author":"Penagini","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.clinthera.2022.06.004_bib0007","article-title":"Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn\u2019s disease\u2014a systematic review with meta-analysis","author":"Attauabi","year":"2021","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.clinthera.2022.06.004_bib0008","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/ecco-jcc\/jjab058","article-title":"Vedolizumab and anti-tumour necrosis factor \u03b1 real-world outcomes in biologic-na\u00efve inflammatory bowel disease patients: results from the EVOLVE study","volume":"15","author":"Bressler","year":"2021","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.clinthera.2022.06.004_bib0009","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12876-018-0868-x","article-title":"Vedolizumab use after failure of TNF-\u03b1 antagonists in children and adolescents with inflammatory bowel disease","volume":"18","author":"Schneider","year":"2018","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.clinthera.2022.06.004_bib0010","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s12328-020-01260-y","article-title":"A pediatric case of moderate active ulcerative colitis successfully treated with vedolizumab in Japan","volume":"14","author":"Ikeuchi","year":"2021","journal-title":"Clin J Gastroenterol"},{"key":"10.1016\/j.clinthera.2022.06.004_bib0011","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1053\/j.gastro.2010.02.047","article-title":"Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response","volume":"138","author":"Turner","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2022.06.004_bib0012","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2147\/CE.S179053","article-title":"Vedolizumab in the treatment of ulcerative colitis: an evidence-based review of safety, efficacy, and place of therapy","volume":"15","author":"Takatsu","year":"2020","journal-title":"Core Evid"},{"key":"10.1016\/j.clinthera.2022.06.004_bib0013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165435","article-title":"Systematic review with network meta-analysis: comparative efficacy of biologics in the treatment of moderately to severely active ulcerative colitis","volume":"11","author":"Vickers","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.clinthera.2022.06.004_bib0014","doi-asserted-by":"crossref","first-page":"S382","DOI":"10.14309\/00000434-201810001-00681","article-title":"Failure of vedolizumab as first-line biologic does not decrease response rates of second-line therapy","volume":"113","author":"Ritter","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2022.06.004_bib0015","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1002\/ibd.22917","article-title":"Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease","volume":"18","author":"D'Haens","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.clinthera.2022.06.004_bib0016","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.dld.2008.01.017","article-title":"Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease","volume":"40","author":"Canani","year":"2008","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.clinthera.2022.06.004_bib0017","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/apt.13308","article-title":"Consecutive monitoring of faecal calprotectin during mesalazine suppository therapy for active rectal inflammation in ulcerative colitis","volume":"42","author":"Yamamoto","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2022.06.004_bib0018","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/gast.2000.8523","article-title":"Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease","volume":"119","author":"Tibble","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2022.06.004_bib0019","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/ecco-jcc\/jjaa189","article-title":"Week 6 calprotectin best predicts likelihood of long-term endoscopic healing in Crohn's disease: a post-hoc analysis of the UNITI\/IM-UNITI trials","volume":"15","author":"Narula","year":"2021","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.clinthera.2022.06.004_bib0020","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/MPG.0000000000003291","article-title":"Early change in fecal calprotectin predicts one-year outcome in children newly diagnosed with ulcerative colitis","volume":"74","author":"Krishnakumar","year":"2022","journal-title":"J Pediatr Gastroenterol Nutr"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822002168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822002168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:56:09Z","timestamp":1758963369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291822002168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0149291822002168"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.06.004","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vedolizumab as the First-Line of Biologicals for Pediatric Patients With Ulcerative Colitis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}